CD19 and acute lymphoblastic leukemia: In conclusion, we have successfully generated CAR-T cells that specifically target CD19 and obtained a CD19-negative refractory relapsed B-ALL cell line, providing a new in vitro model for exploring the treatment of r/r B-ALL patients with low antigen density.